科华生物：“百日咳杆菌核酸检测试剂盒”等产品取得医疗器械注册证

Core Viewpoint - Kehua Bio's subsidiary Suzhou Tianlong and wholly-owned subsidiary Xi'an Kehua have received medical device registration certificates for in vitro diagnostic reagents from the National Medical Products Administration and Shaanxi Provincial Medical Products Administration, which will enhance the company's product line and positively impact business development, although the future revenue impact remains uncertain [1] Group 1 - The company has received registration certificates for three new products: whooping cough bacillus nucleic acid detection kit, carbohydrate antigen 242 determination kit, and carbohydrate antigen 50 determination kit [1] - The new product registration will enrich the company's product offerings [1] - The impact on future operating income is currently unpredictable [1]